切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2007, Vol. 01 ›› Issue (01) : 48 -51. doi: 10.3877/cma.j.issn.1674-0807.2007.01.016

所属专题: 经典病例

综述

类固醇受体辅活化因子家族与乳腺癌
唐鹏1, 姜军1   
  1. 1.400038 重庆,第三军医大学西南医院乳腺疾病中心
  • 收稿日期:2006-11-18 出版日期:2007-01-25

Steroid receptor coactivator family and breast cancer

Peng Tang, Jun Jiang   

  • Received:2006-11-18 Published:2007-01-25
引用本文:

唐鹏, 姜军. 类固醇受体辅活化因子家族与乳腺癌[J/OL]. 中华乳腺病杂志(电子版), 2007, 01(01): 48-51.

Peng Tang, Jun Jiang. Steroid receptor coactivator family and breast cancer[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2007, 01(01): 48-51.

[1]
Onate S A, Tsai S Y, Tsai M J,etal.Sequence and characterization of a coactivator for the steroid hormone receptor superfamily[J].Science,1995,270:1354 -1 3 5 7.
[2]
Takeshita A, Yen P M, Misiti S, etal.Molecular cloning and properties of a full-length putative thyroid hormone receptor coactivator [J].Endocrinology,1996,137:3594 -3597.
[3]
Kamei Y, Xu L, Heinzel T,etal.A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors[J].Cell,1996,85:403 - 414.
[4]
Hong H, Kohli K, Trivedi A,etal.GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors[J].Proc Natl Acad Sci USA,1996,93:4948 - 4952.
[5]
Anzick S L, Kononen J, Walker R L,etal.AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer[J].Science,1997,277:965-968.
[6]
Shiau A K, Barstad D, Loria P M, etal.The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxi fen[J].Cell,1998,95:927-937.
[7]
Leers J, Treuter E,Gustafsson J A.Mechanistic principles in NR box-dependent interaction between nuclear hormone receptors and the coactivator TIF2[J].Mol Cell Biol,1998,18:6001 -6013.
[8]
Chang C, Norris J D, Gron H, etal.Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries discovery of peptide antagonists of estrogen receptors alpha and beta[J].Mol Cell Biol,1999,19:8226-8239.
[9]
Li H, Gomes P J, Chen J D.RAC3, a steroid/nuclear receptor-associated coactivator tha tis related to SRC-1 and TIF2[J].Proc Natl Acad Sci USA,1997,94:8479 -8484.
[10]
Onate S A, Boonyaratanakornkit V, Spencer T E, et al.The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors[J].J Biol Chem,1998,273:12101 -12108.
[11]
Li J, OM'alley B W, Wong J.p300 requires its histone acetyltransferase activity and SRC-1 interaction domain to facilitate thyroid hormone receptor activation in chromatin[J].Mol Cell Biol,2000,20:2031 -2042.
[12]
Chen D, Ma H, Hong H,etal.Regulation of transcription by a protein methyltransferase[J].Science,1999,284:2174 -2177.
[13]
Koh S S, Chen D, Lee Y H, etal.Synergistic enhancement of nuclear receptor function by p160 coactivators and two coactivators with protein methyltransferase activities[J].J Biol Chem,2001,276:1089 -1098.
[14]
Spencer T E, Jenster G, Burcin M M,etal.Steroid receptor coactivator - 1 is a histone acetyltrans ferase[J].Nature,1997,389:194-198.
[15]
Chen H, Lin R J, Schiltz R L,etal.Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300[J].Cell,1997,90:569 -580.
[16]
Carapeti M,Aguiar R C,Chase A,etal.Assignment of the steroid receptor coactivator-1 (SRC-1) gene to human chromosome band 2p23[J].Genomics,1998,52:242 -244.
[17]
Ning G, Jurecic V, Baldini A, etal.Structure and chromosomal locations of mouse steroid receptor coactivator gene family[J].In Vitro Cell Dev Biol Anim,1999,35:481 -486.
[18]
Xu J, Qiu Y, DeMayo F J,etal.Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene[J].Science,1998,279:1922 - 1925.
[19]
Kalkhoven E, Valentine J E, Heery D M,etal.Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate transcription by the oestrogen receptor[J].EMBO J,1998,17:232-243.
[20]
Puustinen R, Sarvilinna N, Manninen T, etal.Localization of glucocorticoid receptor interacting protein 1 in murine tissues using two novel polyclonal antibodies[J].Eur J Endocrinol,2001,145:323-333.
[21]
Picard F, Gehin M, Annicotte J, etal.SRC-1 and TIF2 control energy balance between white and brown adipose tissues[J].Cell,2002,111:931-941.
[22]
Gehin M, Mark M, Dennefeld C,etal.The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP[J].Mol Cell Biol,2002,22:5923 -5937.
[23]
Xu J, Liao L, Ning G,etal.The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development[J].Proc Natl Acad Sci USA,2000,97:6379 -6384.
[24]
Bautista S, Valles H, Walker R L, etal.In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity[J].Clin Cancer Res,1998,4:2925 - 2929.
[25]
Bouras T, Southey M C, Venter D J.Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu[J].Cancer Res,2001,61:903 -907.
[26]
List H J, Reiter R, Singh B,etal.Expression of the nuclear coactivator AIB1 in norma land malignant breast tissue[J].Breast Cancer Res Treat,2001,68:21 - 28.
[27]
Osborne C K, Bardou V, Hopp T A, etal.Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breas tcancer[J].J Natl Cancer Inst,2003,95:353-361.
[28]
Shou J, Massarweh S, Osborne C K, etal.Mechanisms of tamoxifen resistance:increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer[J].J Natl Cancer Inst,2004,96:926-935.
[29]
Louie M C, Zou J X, Rabinovich A, etal.ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance[J].Mol Cell Biol,2004,24:5157-5171.
[30]
Tilli M T, Reiter R, Oh A S,etal.Overexpression of an N-terminally truncated isoform of the nuclear receptor coactivator amplified in breast cancer 1 leads to altered proliferation of mammary epithelial cells in transgenic mice[J].Mol Endocrinol,2005,19:644 -656.
[31]
Planas-Silva M D, Shang Y, Donaher J L,etal.AIB1 enhances estrogen-dependent induction of cyclin D1 expression[J].Cancer Res,2001,61:3858-3862.
[32]
Kuang S Q, Liao L, Zhang H, etal.AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice[J].Cancer Res,2004,64:1875 -1885.
[33]
Liao L, Kuang S Q, Yuan Y,etal.Molecular structure and biological function of the cancer-amplified nuclear receptor coactivator SRC-3/AIB1[J].J Steroid Biochem Mol Biol,2002,83:3 -14.
[34]
List H J, Lauritsen K J, Reiter R, etal.Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependen tgrowth of human MCF-7 breas tcancer cells[J].J Biol Chem,2001,276:23763-23768.
[35]
Berns E M, Staveren I L, Klijn J G,etal.Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer[J].Breast Cancer Res Treat,1998,48:87 - 92.
[36]
Myers E, Fleming F J, Crotty T B,etal.Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer[J].Br J Cancer,2004,91:1687 -1693.
[37]
Newman S P, Bates N P, Vernimmen D, etal.Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer[J].Oncogene,2000,19:490 -497.
[38]
Fleming F J,Myers E, Kelly G,etal.Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer, a predictive role for SRC-1[J].J Clin Pathol,2004,57:1069-1074.
[39]
Eddie M, Arnold H, Enda M D,etal.Recurrence in HER2 over-expressing breast cancer-a predictive role for PEA3 and SRC-1[J].J Am Coll Surg,2004,199:89.
[40]
Kishimoto H, Wang Z, Bhat-Nakshatri P,etal.The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1 alpha/CXCL12[J].Carcinogenesis,2005,26:1706 -1715.
[41]
Lee S K, Kim H J, Kim J W,etal.Steroid receptor coactivator-1 and its family members differentially regulate transactivation by the tumor suppressor protein p53[J].Mol Endocrinol,1999,13:1924-1933.
[1] 洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 571-579.
[2] 赵阳, 肖迎聪, 巨艳, 党晓智, 蔡林利, 薛文欣, 李洋, 肖瑶, 郭妤绮, 宋宏萍. 自动乳腺超声联合免疫组化早期预测乳腺癌新辅助化疗病理完全缓解的临床价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(04): 361-369.
[3] 刘伟, 牛云峰, 安杰. LINC01232 通过miR-516a-5p/BCL9 轴促进三阴性乳腺癌的恶性进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 330-338.
[4] 杨柳, 宋振川, 王新乐. 乳腺癌改良根治术联合背阔肌复位的临床疗效评估[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 269-273.
[5] 牛海刚, 郭文科. 三阴性乳腺癌组织中双特异性磷酸酶14与核受体相互作用蛋白1的表达及预后价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(04): 199-205.
[6] 张钊, 骆成玉, 张树琦, 何平, 李旭斌. 不同术式治疗早期乳腺癌的效果及并发症发生率、复发率比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 494-497.
[7] 宋佳, 汪波, 孙凯律, 商江峰, 吴旦平, 肇毅. 吲哚菁绿荧光显影联合亚甲蓝染色在乳腺癌前哨淋巴结活检中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 498-501.
[8] 孙建娜, 孔令军, 任崇禧, 穆坤, 王晓蕊. 266例首诊Ⅳ期乳腺癌手术患者预后分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 502-505.
[9] 唐丹萍, 王萍, 江孟蝶, 杨晓蓉. 自体脂肪移植在乳腺癌术后乳房重建的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 582-585.
[10] 黄程鑫, 陈莉, 刘伊楚, 王水良, 赖晓凤. OPA1 在乳腺癌组织的表达特征及在ER阳性乳腺癌细胞中的生物学功能研究[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(05): 275-284.
[11] 刘琦, 王守凯, 王帅, 苏雨晴, 马壮, 陈海军, 司丕蕾. 乳腺癌肿瘤内微生物组的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 841-845.
[12] 王帅, 张志远, 苏雨晴, 李雯雯, 王守凯, 刘琦, 李文涛. 孟德尔随机化及其在乳腺癌研究中的应用进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 671-676.
[13] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[14] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[15] 张梦婷, 穷拉姆, 色珍, 李逸群, 德庆旺姆. 西藏地区藏族乳腺癌新辅助化疗的真实世界研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 441-446.
阅读次数
全文


摘要